Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
Performance assessment of a new serological diagnostic test for COVID-19 with candidate peptides from spike and nucleocapsid viral proteins.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cavalcanti-Dantas Vanessa de Melo, da Silva Alan Frazão, Mendes Andrei Félix, de Araújo Júnior Waldecir Oliveira, Bernardo-Menezes Lucas Coêlho, Bresani-Salvi Cristiane Campello, Castellano Lúcio Roberto Cançado, Fernandes Ana Isabel Vieira, Lemos Sherlan Guimarães, de Magalhães Jurandy Júnior Ferraz, Oliveira Renato Antônio Dos Santos, de Assis Priscilla Anne Castro, de Souza Joelma Rodrigues, de Morais Clarice Neuenschwander Lins
Аннотация
Numerous commercial tests for the serological diagnosis of COVID-19 have been produced in recent years. However, it is important to note that these tests exhibit significant variability in their sensitivity, specificity, and accuracy of results. Therefore, the objective of this study was to utilize bioinformatics tools to map SARS-CoV-2 peptides, with the goal of developing a new serological diagnostic test for COVID-19. Two peptides from the S protein and one from the N protein were selected and characterized in silico, chemically synthesized, and used as a serological diagnostic tool to detect IgM, IgG, and IgA anti-SARS-CoV-2 antibodies through the ELISA technique, confirmed as positive and negative samples by RT-qPCR or serology by ELISA. The results showed a sensitivity, specificity, Positive Predictive Value and Negative Predictive Value of 100% (p < 00001, 95% CI) for the proposed test. Although preliminary, this study brings proof-of-concept results that are consistent with the high-performance rates of the ELISA test when compared to other well-established methods for diagnosing COVID-19.